BioCentury | Aug 26, 2020

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...
BioCentury | Aug 14, 2020
Translation in Brief

Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more

Hesperos’ Human-on-a-Chip techIn an Advanced Therapeutics paper, a University of Central Florida team led by Hesperos Inc. co-founder and chief scientist James Hickman tested the efficacy of...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

Maryland team highlights 17 approved drugs that could be repurposed for COVID-19 A University of Maryland team identified 17 FDA-approved drugs that could be repurposed for COVID-19. Reported in a preprint posted Friday to bioRxiv,...
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...
BioCentury | Dec 19, 2019

Skin grafts based on CRISPR-edited iPS cells to treat epidermolysis bullosa

DISEASE CATEGORY: Dermatology INDICATION: Blistering disorder Skin grafts based on CRISPR-edited induced pluripotent stem (iPS) cells could treat recessive dystrophic epidermolysis bullosa, a blistering disorder caused by mutations in COL7A1. Generation of the full-thickness grafts...
BioCentury | Oct 17, 2019

Boosting YY1 expression to treat diabetic nephropathy

DISEASE CATEGORY: Renal INDICATION: Diabetic nephropathy Promoting the expression of YY1, which represses TGFB1 transcription, could treat diabetic nephropathy. In renal biopsy samples, low levels of YY1 and high levels of TGFB1 were associated with...
BioCentury | Aug 23, 2019
Clinical News

GSK notches clinical win with anti-BCMA ADC amid cancer pipeline push

GlaxoSmithKline's return to cancer took another large step forward as one of its most prominent oncology candidates succeeded in a pivotal Phase II trial to treat multiple myeloma. On Friday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BioCentury | Jun 29, 2019

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Jun 10, 2019
Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

In its ongoing quest to find combinations for Keytruda pembrolizumab, Merck is acquiring two-year-old Tilos for its ability to modulate TGFβ, a target that’s been gaining interest on the back of clinical data in immuno-oncology,...
Items per page:
1 - 10 of 234